Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COC-IDCB: Neoadjuvant Chemotherapy in Breast Cancer
NCT02897700Phase 1Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jan 2013
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cyclophosphamide, pegylated liposomal doxorubicin, epirubicin, fluorouracil and methotrexate in breast cancer (3 arms), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Incidence of treatment-emergent adverse events at 6 months. Started Jan 2013; status: recruiting.
02
Drugs
cyclophosphamidepegylated liposomal doxorubicinepirubicinfluorouracilmethotrexate
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02897700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02897700.